Nobody complains that we have more cancer medicines available today than in the 1980s. Why should we complain about having ...
Breaking: The WHO issued its starkest warning yet on the consequences of the abrupt cessation of U.S. global health funding, ...
The Trump administration has canceled funding for an ongoing 30-year, nationwide study tracking patients with prediabetes and ...
How a case involving Dana-Farber Cancer Institute illustrates the potential risks for institutions when star doctors give ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.
The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...
A Texas midwife has been arrested and accused of providing illegal abortions, Texas Attorney General Ken Paxton announced ...
The Trump administration earlier this year ordered all government employees to return to work in person. FDA employees whose ...
Basically, a brand-name drug company settles a patent infringement lawsuit by paying cash or transferring something else of ...
Before the hearing, Oz hadn’t spoken much about pressing health policy issues since he was nominated for the crucial post.
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
In today's Pharmalittle roundup, we're reading about Medicare negotiations, U.K. drug rebates rising, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback